3D Mol Similar

Domperidone

Iupac Name：6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one

CAS No.: 57808-66-9

Molecular Weight：425.917

Modify Date.: 2022-11-25 02:23

Introduction:

Peripheral dopamine receptor antagonist that does not cross the blood-brain barrier; anti-emetic.

View more+

Request For Quotation

1. Names and Identifiers

1.1 Name: Domperidone
1.2 Synonyms: 1H-Benzimidazol-2-ol, 5-chloro-1-[1-[3-(2-hydroxy-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]- 2H-Benzimidazol-2-one, 5-chloro-1-[1-[3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl]-4-piperidinyl]-1,3-dihydro- 5-Chloro-1-[1-[3-(2-oxo-1-benzimidazolyl)propyl]-4-piperidyl]benzimidazol-2-one 5-Chloro-1-{1-[3-(2-hydroxy-1H-benzimidazol-1-yl)propyl]-4-piperidinyl}-1H-benzimidazol-2-ol 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-1,3-benzodiazol-1-yl)propyl]piperidin-4-yl}-2,3-dihydro-1H-1,3-benzodiazol-2-one 5-Chloro-1-{1-[3-(2-oxo-2,3-dihydro-1H-benzimidazol-1-yl)propyl]-4-piperidinyl}-1,3-dihydro-2H-benzimidazol-2-one 5-chloro-1-{1-[3-(2-oxo-2,3-dihydro-1h-benzimidazol-1-yl)propyl]piperidin-4-yl}-1,3-dihydro-2h-benzimidazol-2-one 6-chloro-3-[1-[3-(2-oxo-3H-benzimidazol-1-yl)propyl]piperidin-4-yl]-1H-benzimidazol-2-one DOMPERIDONE BASE DoMperidone Sustained Release Pellets Domperidone,Motilium DoMperidone-d6 EINECS 260-968-7 kw-5338 MFCD00069256 midazol-1-yl)propyl)-4-piperidinyl)- MOD Motilium

1.3 CAS No.: 57808-66-9

1.4 CID: 3151

1.5 EINECS(EC#): 260-968-7

1.6 Molecular Formula: C22H24ClN5O2 (isomer)

1.7 Inchi: InChI=1S/C22H24ClN5O2/c23-15-6-7-20-18(14-15)25-22(30)28(20)16-8-12-26(13-9-16)10-3-11-27-19-5-2-1-4-17(19)24-21(27)29/h1-2,4-7,14,16H,3,8-13H2,(H,24,29)(H,25,30)

1.8 InChkey: FGXWKSZFVQUSTL-UHFFFAOYSA-N

1.9 Canonical Smiles: C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O

1.10 Isomers Smiles: C1CN(CCC1N2C3=C(C=C(C=C3)Cl)NC2=O)CCCN4C5=CC=CC=C5NC4=O

2. Properties

2.1 Density: 1.341

2.1 Melting point: 242.5 oC

2.1 Boiling point: 723.6±70.0 °C at 760 mmHg

2.1 Refractive index: 1.5400 (estimate)

2.1 Flash Point: 391.4±35.7 °C

2.1 Precise Quality: 425.16200

2.1 PSA: 78.82000

2.1 logP: 3.29110

2.1 Solubility: DMSO: >10?mg/mL

2.2 Appearance: Solid

2.3 Storage: Ambient temperatures.

2.4 Color/Form: Powder

2.5 Physical: Solid

2.6 pKa: pKa 7.90 (Uncertain)

2.7 Water Solubility: Slightly soluble in water.

2.8 Stability: Stable. Incompatible with strong oxidizing agents.

2.9 StorageTemp: Store at RT

3. Use and Manufacturing

3.1 Definition: ChEBI: 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used s an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet reparations.

3.2 GHS Classification: Signal: Warning
GHS Hazard Statements
Aggregated GHS information provided by 74 companies from 6 notifications to the ECHA C&L Inventory.

Reported as not meeting GHS hazard criteria by 1 of 74 companies. For more detailed information, please visit ECHA C&L website

Of the 5 notification(s) provided by 73 of 74 companies with hazard statement code(s):

H361 (89.04%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]

Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown.

Precautionary Statement Codes
P201, P202, P281, P308+P313, P405, and P501

3.3 Usage: Peripheral dopamine receptor antagonist that does not cross the blood-brain barrier; anti-emetic.

4. Safety and Handling

4.1 Symbol: GHS08

4.1 Hazard Codes: Xn

4.1 Signal Word: Warning

4.1 Risk Statements: R62;R63

4.1 Safety Statements: S26;S36

4.1 Hazard Declaration: H361

4.1 RIDADR: NONH for all modes of transport

4.1 Caution Statement: P280

4.1 WGK Germany: 3

4.1 RTECS: DE2275900

4.1 Safety: Poison by intravenous and intraperitoneal routes. Human systemic effects by intravenous and intramuscular routes: eye effects, convulsions, muscle spasms and cardiac arrhythmias. Experimental teratogenic and reproductive effects. When heated to decomposition it emits toxic fumes of Cl^? and NO_x.
Hazard Codes:?Xn
Risk Statements: 62-63?
R62: Risk of impaired fertility.?
R63: Possible risk of harm to the unborn child.
Safety Statements: 26-36
S26: In case of contact with eyes, rinse immediately with plenty of water and seek medical advice.?
S36: Wear suitable protective clothing.
WGK Germany of Domperidone (CAS NO.57808-66-9): 3?

4.2 Specification: ? Domperidone (CAS NO.57808-66-9), its Synonyms are 2H-Benzimidazol-2-one, 1,3-dihydro-5-chloro-1-(1-(3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl)-4-piperidinyl)- ; 2H-Benzimidazol-2-one, 5-chloro-1-(1-(3-(2,3-dihydro-2-oxo-1H-benzimidazol-1-yl)propyl)-4-piperidinyl)-1,3-dihydro- ; 5-Chloro-1-(1-(3-(2-oxo-1-benzimidazolinyl)propyl)-4-piperidyl)-2-benzimidazolinone ; Domperidonum ; Motilium . It is white powder.

4.3 Toxicity

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
dog	LD50	intravenous	42700ug/kg (42.7mg/kg)	BEHAVIORAL: ATAXIA BEHAVIORAL: ANTIPSYCHOTIC GASTROINTESTINAL: NAUSEA OR VOMITING	Archives Internationales de Pharmacodynamie et de Therapie. Vol. 244, Pg. 130, 1980.
dog	LD50	oral	> 160mg/kg (160mg/kg)	?	Archives Internationales de Pharmacodynamie et de Therapie. Vol. 244, Pg. 130, 1980.
dog	LD50	rectal	> 120mg/kg (120mg/kg)	?	Yakkyoku. Pharmacy. Vol. 35, Pg. 625, 1984.
dog	LD50	subcutaneous	> 160mg/kg (160mg/kg)	?	Archives Internationales de Pharmacodynamie et de Therapie. Vol. 244, Pg. 130, 1980.
guinea pig	LD50	intravenous	42900ug/kg (42.9mg/kg)	BEHAVIORAL: ATAXIA GASTROINTESTINAL: NAUSEA OR VOMITING BEHAVIORAL: ANTIPSYCHOTIC	Archives Internationales de Pharmacodynamie et de Therapie. Vol. 244, Pg. 130, 1980.
human	LDLo	intravenous	429ug/kg (0.429mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	British Medical Journal. Vol. 288, Pg. 1728, 1984.
human	TDLo	intravenous	714ug/kg (0.714mg/kg)	BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD	British Medical Journal. Vol. 288, Pg. 1728, 1984.
infant	TDLo	oral	1170ug/kg/1D- (1.17mg/kg)	SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE	Journal of Pediatrics. Vol. 108, Pg. 630, 1986.
man	TDLo	intramuscular	200ug/kg (0.2mg/kg)	SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)	Lancet. Vol. 2, Pg. 1259, 1980.
man	TDLo	oral	234mg/kg/39W- (234mg/kg)	ENDOCRINE: GYNECOMASTIA	Postgraduate Medical Journal. Vol. 67, Pg. 401, 1991.
mouse	LD50	intraperitoneal	> 8gm/kg (8000mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)	Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 8, Pg. 3991, 1980.
mouse	LD50	intravenous	46500ug/kg (46.5mg/kg)	SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION	Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 8, Pg. 3991, 1980.
mouse	LD50	oral	> 8gm/kg (8000mg/kg)	?	Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 13, Pg. 1128, 1982.
mouse	LD50	subcutaneous	> 8gm/kg (8000mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY)	Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 8, Pg. 3991, 1980.
rat	LD50	intraperitoneal	61200ug/kg (61.2mg/kg)	?	Iyakuhin Kenkyu. Study of Medical Supplies. Vol. 13, Pg. 1128, 1982.
rat	LD50	intravenous	41700ug/kg (41.7mg/kg)	SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION	Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 8, Pg. 3991, 1980.
rat	LD50	oral	5243mg/kg (5243mg/kg)	SENSE ORGANS AND SPECIAL SENSES: PTOSIS: EYE BEHAVIORAL: ATAXIA LUNGS, THORAX, OR RESPIRATION: DYSPNEA	Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 8, Pg. 3991, 1980.
rat	LD50	rectal	> 250mg/kg (250mg/kg)	?	Yakkyoku. Pharmacy. Vol. 35, Pg. 625, 1984.
rat	LD50	subcutaneous	> 8gm/kg (8000mg/kg)	SENSE ORGANS AND SPECIAL SENSES: LACRIMATION: EYE BEHAVIORAL: ALTERED SLEEP TIME (INCLUDING CHANGE IN RIGHTING REFLEX) LUNGS, THORAX, OR RESPIRATION: CYANOSIS	Yakuri to Chiryo. Pharmacology and Therapeutics. Vol. 8, Pg. 3991, 1980.
women	TDLo	intravenous	600ug/kg/1D (0.6mg/kg)	CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION)	Lancet. Vol. 2, Pg. 385, 1985.
women	TDLo	intravenous	1mg/kg (1mg/kg)	CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION)	British Medical Journal. Vol. 289, Pg. 1579, 1984.
women	TDLo	rectal	7200ug/kg/30H (7.2mg/kg)	SENSE ORGANS AND SPECIAL SENSES: OTHER: EYE	Journal of Pediatrics. Vol. 105, Pg. 852, 1984. ?

View all

5. MSDS

2.Hazard identification

2.1 Classification of the substance or mixture

Reproductive toxicity, Category 2

2.2 GHS label elements, including precautionary statements

Pictogram(s)
Signal word	Warning
Hazard statement(s)	H361 Suspected of damaging fertility or the unborn child
Precautionary statement(s)
Prevention	P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P280 Wear protective gloves/protective clothing/eye protection/face protection.
Response	P308+P313 IF exposed or concerned: Get medical advice/ attention.
Storage	P405 Store locked up.
Disposal	P501 Dispose of contents/container to ...

2.3 Other hazards which do not result in classification

none

View all

6. NMR Spectrum

13C NMR : Predict

1H NMR : Predict

Predict 1H proton NMR

7. Other Information

7.0 Merck: 14,3418

7.1 Pharmacodynamics: Domperidone is a specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.

7.2 Side effects: Side effects associated with domperidone include dry mouth, abdominal cramps, diarrhea, nausea, rash, itching, hives, and hyperprolactinemia (the symptoms of which may include breast enlargement, galactorrhea, breast pain/tenderness, gynecomastia, hypogonadism, and menstrual irregularities).

7.3 Gastro-kinetic drugs: Domperidone is a commonly used antiemetic and gastro-kinetic drug with its appearance being white to light yellow powder and bitter taste. It is almost insoluble in water, slightly soluble in ethanol, easily soluble in lactic acid as well as soluble in citrate. This product is a kind of peripheral dopamine receptor antagonists with strong action. Domperidone can block the DA1 and DA2 receptor next to the synapses, antagonizing the inhibitory effect of dopamine on the postsynaptic cholinergic neurons of myenteric plexus and causing the stomach contractions. It can promote the motility and tension of digestive tract motility to return to normal function, promoting the emptying of stomach, increasing the motility of gastric antral and duodenum, coordinating the contraction of the pylorus as well as enhancing the esophageal peristalsis and the tension of the lower esophageal sphincter. Because it has a poor penetration capability through the blood-brain barrier with almost no antagonism on the dopamine receptor, you can rule out the side effects of spirit and the central nervous system side. It has rapid absorption after oral administration with the plasma concentration reaching peak after 15~30 min. In addition to the central nervous system, it is also widely distributed in other parts of the body. Owing to the presence of "first pass" hepatic metabolism and intestinal metabolism, it has a low oral bioavailability. The half-life of this product is 7h with 30% excreted through the urine at 24 h after the oral administration and about 60% excreted through faeces within 4 days.
Indications
1, Digestion dysfunction symptoms caused by delayed gastric emptying, gastroesophageal reflux, chronic gastritis and esophagitis including nausea, vomiting, belching, abdominal fullness, abdominal pain, regurgitation caused burning sensation of mouth and stomach.
2, Parkinson's disease and nausea and vomiting caused by various kinds of reasons such as functional, infection, dietary, radiotherapy or drug therapy and dopamine receptor agonists (such as levodopa, bromocriptine) therapy.
3, it is suitable for treating migraine, dysmenorrhea, traumatic brain injury and intracranial lesions, radiation therapy and the nausea and vomiting caused by levodopa, nonsteroidal anti-inflammatory drug.
4, it is effective in treating the nausea and vomiting caused by various organic or functional gastrointestinal disorders in elderly people.
5, Domperidone is not effective in treating the vomiting caused by surgery or anesthesia and chemotherapy.

7.4 Chemical Properties: From dimethylformamide-water to obtain its white crystalline powder; the melting points is 242.5 ℃

7.5 Uses: It is a kind of potent peripheral dopamine receptor antagonist with anti-vomiting and gastro-kinetic effects. It can affect the gastrointestinal motility to make the motility and tension of upper gastrointestinal tract return to normal and promote gastric emptying, enhancing the antral and duodenal motility, and coordinating the pyloric contraction. It can be used for the treatment of dyspepsia, and the nausea and vomiting induced by functional, organic, infection, dietary, radiation therapy or drug therapy. Because it almost has no inhibitory effect on dopamine receptor, there are no psychiatric and neurological side effects. And it can be used for treating the nausea caused by treating the Parkinson’s disease through taking dopamine agonists.
It can be used as anticholinergic antispasmodics.
Domperidone is a kind of phenyl imidazole compounds with a strong role in promoting gastric motility and antiemetic effect. It can strengthen the tension of the sphincter of the lower part of the esophagus, preventing the stomach-esophageal reflux, enhancing the gastric motility, promoting the gastric emptying, coordinating the stomach and duodenal motility, suppressing nausea, vomiting, and effectively preventing the bile reflux without affecting the secretion of gastric juice. This product is a kind of peripheral dopamine receptor antagonists which can directly block the gastrointestinal dopamine receptors and exhibit the stimulating effect of gastric motility. It can enhance the esophageal peristalsis and the tension of esophageal sphincter. Because of its poor penetration through the blood brain barrier, it has almost no antagonism against the dopamine receptor of the brain, and therefore can excluding the side effects of the spirit and the central nervous system.

7.6 Production method: 2-nitro-1, 4-dichlorobenzene is reacted with 4-amino-cyclohexanecarboxylic acid ethyl ester and is further subject to hydrogenation reduction, urea cyclization, hydrolysis, to give 5-chloro-1-(piperidin-4-yl)-1,3-dihydro-benzimidazol-2-ketone.
Hydroxyl propylamine can have nucleophilic substitution of the chlorine of 2-nitro-chlorobenzene and then be subject to hydrogenation to reduce the nitro group to amino group; then have cyclization with potassium chloride and further chlorination to give 1-(3-chloropropyl)-2,3-dihydro-1H-benzimidazol-2-ketone.
The two benzimidazole derivative obtained above are processed as follows and can give domperidone. 2.3 parts of 1-(3-chloropropyl)-2,3-dihydro-1H-benzimidazol-2-ketone, 2.5 parts of 5--chloro-I-(piperidin-4-yl)-1,3-2H-dihydro-benzimidazol-2-one, 3.2 parts of sodium carbonate, 0.1 parts of potassium iodide and 80 parts of 4-methyl-2-pentanone were stirred and reflux for 24h. After being cooled to room temperature, add water, filter off the insolubles and purify it by silica gel column chromatography with the eluting solution being chloroform and 10% methanol mixture. The effluent containing the product were collected and concentrated. The residue was crystallized using 4-methyl-2-pentanone. After filtration, apply re-crystallization with the mixture of dimethylformamide and water to obtain 1.3 parts of domperidone with the yield being 30% and the mp being 242.5 ℃.

7.7 Chemical Properties: White or almost white powder.

7.8 Originator: Motilium,Cilag,Switz.,1979

7.9 Uses: COX2 inhibitor, antiinflammatory, antiarthritic

7.10 Uses: A novel peripheral dopamine receptor antagonist that does not cross the blood-brain barrier; anti-emetic. Domperidone(Motilium) is a dopamine blocker and an antidopaminergic reagent.

7.11 Uses: For management of dyspepsia, heartburn, epigastric pain, nausea, and vomiting.

7.12 Definition: ChEBI: 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used s an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet reparations.

7.13 Dissociation Constants: 7.9

7.14 Collision Cross Section: 201.8 ?2 [M+H]+ [CCS Type: TW, Method: calibrated with polyalanine and drug standards]

7.15 Mesh: Drugs that bind to but do not activate DOPAMINE RECEPTORS, thereby blocking the actions of dopamine or exogenous agonists. Many drugs used in the treatment of psychotic disorders (ANTIPSYCHOTIC AGENTS) are dopamine antagonists, although their therapeutic effects may be due to long-term adjustments of the brain rather than to the acute effects of blocking dopamine receptors. Dopamine antagonists have been used for several other clinical purposes including as ANTIEMETICS, in the treatment of Tourette syndrome, and for hiccup. Dopamine receptor blockade is associated with NEUROLEPTIC MALIGNANT SYNDROME. (See all compounds classified as Dopamine Antagonists.)|Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)

7.16 Metabolism: Domperidone has known human metabolites that include 1-Propyl-1,3-dihydro-2H-benzimidazol-2-one, 3-[3-[4-(5-Chloro-2-oxo-3H-benzimidazol-1-yl)piperidin-1-yl]propyl]-6-hydroxy-1H-benzimidazol-2-one, and 5-Chloro-1-(piperidin-4-yl)-1H-benzo[d]imidazol-2(3H)-one.

7.17 Biological Half Life: 7 hours

7.18 Mesh Entry Terms: Apo Domperidone

7.19 Use Classification: Animal Drugs -> FDA Approved Animal Drug Products (Green Book) -> Active Ingredients

7.20 Usage: Domperidone is used as a Peripheral dopamine receptor antagonist that does not cross the blood-brain barrier. The antidopaminergic effects of Domperidone have been correlated to antiemetic and gastroprokinetic action.

7.21 Manufacturing Process: A mixture of 2.3 parts of 1-(3-chloropropyl)-1,3-dihydro-2H-benzimidazol-2- one, 2.5 parts of 5-chloro-1,3-dihydro-l-(4-piperidinyl)-2H-benzimidazol-2- one, 3.2 parts of sodium carbonate, 0.1 part of potassium iodide and 80 parts of 4-methyl-2-pentanone is stirred and refluxed for 24 hours. The reaction mixture is cooled to room temperature and water is added. The undissolved product is filtered off and purified by column chromatography over silica gel using a mixture of trichloromethane and 10% methanol as eluent. The pure fractions are collected and the eluent is evaporated. The residue is crystallized from 4-methyl-2-pentanone. The product is filtered off and recrystallized from a mixture of N,N-dimethylformamide and water, yielding 1.3 parts (30%) of 5- chloro-1-[1-[3-(1,3-dihydro-2-oxo-2H-benzimidazol-1-yl)propyl]-4- piperidinyl]-1,3-dihydro-2H-benzimidazol-2-one; MP 242.5°C.

7.22 Brand name: Motilium (Janssen);Evixub;Kw 5338;Moperidona;Neta662;R 33812;Tametil;Touristic.

7.23 Therapeutic Function: Antiemetic

7.24 World Health Organization (WHO): Domperidone, a peripheral dopaminergic antagonist, was introduced in 1979 for the symptomatic relief of acute nausea and vomiting. The major manufacturer became aware that the injectable formulation was being used in some countries in much higher doses than those recommended to combat nausea and vomiting in cancer patients treated with cytostatic agents. Such use - which was not in conformity with the approved indications - was associated with cardiotoxicity, which in some cases was fatal, and the manufacturer decided to withdraw the injectable dosage form from the market worldwide in January 1985. Suppositories, tablets and a suspension remain available and the manufacturer continues to supply the injection for the treatment of a named patient at the written request of a doctor on the understanding that the appropriate dosage recommendations will be followed.

7.25 Biological Activity: Peripheral dopamine D 2 -like receptor antagonist that does not readily cross the blood brain barrier. Displays gastroprokinetic and antiemetic properties; increases the frequency and duration of antral and duodenal contractions and protects from apomorphine-induced emesis (ED 50 values are 0.003 and 0.03 mg/kg for i.v. and oral administration respectively).

7.26 Veterinary Drugs and Treatments: Domperidone may be useful for treatment of fescue toxicosis in pregnant mares or as a prokinetic or antiemetic agent in small animals. It has more effect on conditions with delayed gastric emptying than other GI hypomotility conditions.
Via its effects on prolactin, domperidone may also be used to stimulate milk production in horses and small animals.
Domperidone has been shown to increase plasma ACTH in horses with equine pituitary pars intermedia dysfunction (Equine Cushing’s) and may be useful in helping diagnose this condition.

8. Computational chemical data

Molecular Weight: 425.917g/mol
Molecular Formula: C₂₂H₂₄ClN₅O₂
Compound Is Canonicalized: True
XLogP3-AA: null
Exact Mass: 425.1618527
Monoisotopic Mass: 425.1618527
Complexity: 655
Rotatable Bond Count: 5
Hydrogen Bond Donor Count: 2
Hydrogen Bond Acceptor Count: 3
Topological Polar Surface Area: 67.9
Heavy Atom Count: 30
Defined Atom Stereocenter Count: 0
Undefined Atom Stereocenter Count: 0
Defined Bond Stereocenter Count: 0
Undefined Bond Stereocenter Count: 0
Isotope Atom Count: 0
Covalently-Bonded Unit Count: 1
CACTVS Substructure Key Fingerprint: AAADceB7sAAEAAAAAAAAAAAAAAAAAWLAAAA8YIAAAAAAAFgBQAAAHgIQAAAACCrBECQxwIPAAACIACRCUACCAAAhBwAIiAAIdoiIYCLB05GUIAholgLIyCcQAAAAAABAAAIAACAAAIAABAAAQAAAAAAAAA==

9. Question & Answer

What is Domperidone?Pharmacodynamics,Uses,Side effects,Precautions Jan 09 2020
Domperidone is a specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms. Pharmacodynamics Domperidone is a specific blocker of dopamine receptors. It speeds gastrointestinal...

10. Recommended Suppliers

Global276SuppliersView all >>

Hebei Ruqi technology Diamond member

-122YR

Products:Pharmaceutical intermediates
Tel:+8615373-093998-15373093998
Email:sales02@rulintech.com

DOMPERIDONE BASE

Purity:99%Packing: 200kg/bag FOB
Price: 100 USD/g
Time: 2023/06/06

Inquire

Hebei Bester Biotechnology Co., Ltd. Diamond member

-121YR

Products:pmk powder ;pmk oil ;bmk powder ;bmk oil ;Protonitazene hcl ; Bromazolam ; Metonitazene; 2-Bromo-4'-methylpropiophenone ;
Tel:+86-131-71569950
Email:dree@chbbest.com

99% up GMP DMF Domperidone 57808-66-9

Purity:99%Packing: 200kg/bag FOB
Price: 12 USD/kg
Time: 2023/06/06

Inquire

Qiaoxi Shengyou Chemical Co., LTD Diamond member

-121YR

Products:pharmaceutical intermediates Organic raw materialsAnimal and plant extracts1.4BDO, Eutylone,4MMC, JWH ,SGT Peptide, Steroids, Benzos,Dissociatives
Tel:86-311-18034511316
Email:saleroom@yeah.net

Domperidone 99% white powder 57808-66-9

Purity:99%Packing: 200kg/bag FOB
Price: USD/kg
Time: 2023/06/06

Inquire

Xiamen wonderful Biotechnology Co., Ltd. Diamond member

-122YR

Products:Top quality and high purity with safe transportation and low price
Tel:+86153-59898336-15359898336
Email:aya@xmwonderfulbio.com

CAS57808-66-9 Domperidone

Purity:99%Packing: 200kg/bag FOB
Price: 10 USD/g
Time: 2023/06/06

Inquire

Hebei Chengcai Biotechnology Co., LTD Diamond member

-122YR

Products:We are engaged in the development, marketing and sales of apis, intermediates, natural products (extracts), fine chemicals, food additives, agricultural chemicals and other products.
Tel:0086-0319-19131200228
Email:17610795226@chengcaibio.com

Domperidone CAS 57808-66-9

Purity:99%Packing: 200kg/bag FOB
Price: 1 USD/kg
Time: 2023/06/06

Inquire

11. Realated Product Infomation

118435-03-3 DoMperidone

99497-03-7 Domperidone maleate

142799-22-2 Domperidone Impurity 15

1346598-11-5 DoMperidone EP IMpurity B

1391053-55-6 DoMperidone EP IMpurity F

1614255-34-3 DoMperidone EP IMpurity D

Recently Updated : 1616885-96-1 1617537-86-6 161912-04-5 1619977-74-0 162052-71-3 1620923-59-2 1621066-69-0 1621066-70-3 1621084-02-3 1621224-64-3